Jasper Therapeutics explores strategic alternatives including asset sale or wind-down

Jasper Therapeutics initiated a comprehensive review of strategic alternatives to maximize shareholder value, including potential asset sales, licensing, collaborations, company sale, or orderly wind-down. The clinical-stage biotech company is evaluating cost-saving measures while maintaining regulatory compliance with no defined timeline for the process.